Nov 02

Beyond Biotech Podcast: Natural Killer Cells

Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. was featured on the Beyond Biotech Podcast hosted by Labiotech.eu to discuss recent milestones including:

  • Demonstrating the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials, and
  • Receiving FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoimmune disease.

AlloNK (also known as AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers in the outpatient setting.

Listen to the podcast here.

 

Recent Posts

See All

SDBJ: Artiva Raises $300M to Fund Phase 3 Trial for RA Cell Therapy

Artiva was featured in San Diego Business Journal following its $300 million financing to support the continued advancement of AlloNK® in autoimmune disease. The article discusses the company’s planned Phase 3 trial in refractory rheumatoid arthritis and its focus on developing an outpatient-ready, scalable approach to deep B-cell depletion. Read the article here (subscription may...

Biotech2050 Podcast: Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Over the past decade, CAR-T therapies have demonstrated curative potential, while also underscoring how complexity, cost, and infrastructure can limit the number of patients who can be treated. In this episode of the Biotech2050 podcast, Artiva’s CEO Fred Aslan discusses how lessons from the first generation of CAR-T therapies are shaping new approaches in autoimmune...

Base to Base Biotech Podcast: Natural Killer Cell Therapy

In rheumatoid arthritis, existing therapies frequently fall short of delivering sustained disease control, despite sequential use of biologic and targeted agents. In a this episode of the 𝗕𝗮𝘀𝗲 𝘁𝗼 𝗕𝗮𝘀𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗣𝗼𝗱𝗰𝗮𝘀𝘁, Lisa Guerrettaz, Executive Director, Pharmacology and Translational Science at Artiva Biotherapeutics, discusses how the limitations of currently approved treatments are driving the development...

Secret Link